FDA Cuts Priority Review Voucher Fee By 32%; No Takers For FY 2013

By taking into account the incremental costs of priority review and eliminating the IND aspect of the calculation, the agency reduces the fee to redeem a tropical disease priority review voucher to $3.6 million in fiscal year 2013.